雄激素剥夺治疗与血栓栓塞事件的关联:系统综述与荟萃分析
该系统综述与荟萃分析检索了PubMed、Web of Science和Scopus数据库,纳入报告前列腺癌患者暴露于雄激素剥夺治疗(ADT)后发生血栓栓塞事件的研究。结果显示,不含雌激素的ADT与血栓栓塞事件风险升高相关(RR 1.43,95%CI 1.15-1.77,P=.001),单用雌激素治疗亦与风险升高相关(RR 3.72,95%CI 1.78-7.80,P<.001)。
要点
- 不含雌激素的ADT与血栓栓塞事件风险升高相关(RR 1.43,95%CI 1.15-1.77,P=.001)。
- 单用雌激素治疗与血栓栓塞事件风险升高相关(RR 3.72,95%CI 1.78-7.80,P<.001)。
- 局限期病变中不含雌激素的ADT亦与风险升高相关(RR 1.10,95%CI 1.05-1.16,P<.001)。
核心结论
- 现有证据提示不含雌激素的ADT与血栓栓塞事件风险升高相关。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science、Scopus(2017年4月5日)及WHO国际试验注册平台(2017年6月23日)。
- 采用随机效应荟萃分析计算汇总风险比(RR)及95%置信区间(CI),用I2统计量量化异质性,用Begg和Egger统计量评估小型研究效应。
主要发现
- 10项研究中,不含雌激素的ADT增加血栓栓塞事件风险(RR 1.43,95%CI 1.15-1.77,P=.001)。
- 9项研究中,单用雌激素治疗与血栓栓塞事件风险升高相关(RR 3.72,95%CI 1.78-7.80,P<.001)。
- 局限期病变中,不含雌激素的ADT亦与血栓栓塞事件风险升高相关(RR 1.10,95%CI 1.05-1.16,P<.001)。
- 在局限期病变研究中异质性得到解决,无小型研究效应的证据。
关键数值与推荐
- 纳入标准:报告前列腺癌患者暴露于ADT vs 较低暴露组血栓栓塞事件的研究。
- 研究质量采用纽卡斯尔-渥太华量表(Newcastle-Ottawa Scale)标准评估。
临床怎么用
- 原文未述临床实践建议。
局限性
- 原文未述局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the association of androgen deprivation therapy (ADT) for prostate cancer with thromboembolic events. METHODS: PubMed, Web of Science, and Scopus were queried on April 5, 2017 for systematic review. Additionally, The World Health Organization International Trials Registry Platform was queried on June 23, 2017. Eligible studies reported thromboembolic events among individuals with prostate cancer exposed to ADT vs a lesser-exposed group. Five hundred sixty-nine unique studies were identified with 65 undergoing full-text review. We utilized the Meta-analysis of Observational Studies in Epidemiology statement guidelines and the Cochrane Review Group's data extraction template. Study quality was evaluated by Newcastle-Ottawa Scale criteria. We conducted random-effects meta-analyses to calculate summary statistic risk ratios and 95% confidence intervals. Heterogeneity was quantified using the I2 statistic. Small study effects were evaluated using Begg and Egger statistics. RESULTS: In 10 studies "ADT without estrogen" increased the risk of thromboembolic events (risk ratio [RR] 1.43, 95% confidence interval [CI] 1.15-1.77, P = .001). In 9 studies estrogen therapy alone was associated with an increased risk of thromboembolic events (RR 3.72, 95% CI 1.78-7.80, P <.001). We found an increased risk of thromboembolic events from ADT use without estrogen when limited to localized disease (RR 1.10, 95% CI 1.05-1.16, P <.001). Heterogeneity was resolved in those studies examining localized disease. There was no evidence of small study effects. CONCLUSION: The currently available evidence suggests that ADT without estrogen is associated with an increased the risk of thromboembolic events.
引用
- Nead KT, Boldbaatar N, Yang DD, et al. Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. Urology. 2018. PMID: 29352986. doi:10.1016/j.urology.2017.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。